Bristol-Myers Squibb stock heads into the open after a 0.69% NYSE gain
Published on 09/16/2026 at 04:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock closed at USD 64.08 on the New York Stock Exchange on September 14, 2026, marking a 0.69% gain versus the prior session in regular trading. That close left the shares trading about USD 2.25, or roughly 3.5%, below the prevailing analyst consensus target around USD 66.33 per recent MarketBeat data.
September 14, 2026 in numbers
Bristol-Myers Squibb Inc. (ISIN US1078421011, NYSE: BMY) ended trading on September 14, 2026 at USD 64.08 on its primary venue, up 0.69% from the previous close according to NYSE closing data summarized in recent market overviews. Price data for that session show that the stock’s advance still left it a few dollars under the analyst consensus target of approximately USD 66.33, implying modest potential upside if forecasts are met. Per the same MarketBeat consensus snapshot cited in recent coverage, the shares were valued against fiscal 2026 non-GAAP earnings per share guidance in a range of USD 6.75 to USD 7.00, alongside a consensus estimate around USD 6.95, keeping profit expectations and valuation in focus for investors.MarketBeat In parallel, a broader wrap noted that the USD 64.08 close on September 14, 2026 came as the shares held near that consensus target, with the modest uptick contrasting with pressure in parts of the wider equity market.Ad-hoc-news
Legal and guidance themes today
Into today’s session, investors are watching both earnings expectations and legal risk around key oncology franchises. According to a detailed summary that relayed MarketBeat data, Bristol-Myers Squibb’s fiscal 2026 earnings per share guidance stands in a non-GAAP range of USD 6.75 to USD 7.00, with the consensus forecast around USD 6.95, keeping the trajectory of profitability central to sentiment.Ad-hoc-news In addition, as a recent report from Reuters outlined on September 15, 2026, Bristol-Myers Squibb and its partner Ono Pharmaceutical have sued Amgen in Delaware federal court seeking to block a proposed biosimilar to Opdivo, the company’s blockbuster cancer immunotherapy, highlighting patent defense as a significant strategic factor. The complaint, described in more detail by Bloomberg Law on September 15, 2026, alleges that Amgen’s candidate ABP 206 infringes seven patents related to Opdivo, and the case adds a legal overhang that could influence how the market weighs long-term cash flow from immuno-oncology assets. Together, the guidance framework and the new patent suit shape the backdrop for Bristol-Myers Squibb stock as it heads into the New York session on September 16, 2026.
